Zerion Pharma is featured as an innovative start-up by Pharmaceutical Technology in their ‘Trends in Formulation 2023’ eBook, October 2023.
This article delves into Zerion Pharma's journey, from its inception in 2019 to its current pioneering work in enhancing drug bioavailability. From the company's breakthrough, driven by research at the University of Copenhagen, to strategic partnerships with Arla Food Ingredients and Hovione.
The article explores the innovative Dispersome® technology, powered by natural ingredient β-lactoglobulin, which effectively enhances drug solubility, making it a promising solution for pharmaceutical developers struggling with solubility challenges. With drug loadings exceeding 50% while maintaining stability, and leveraging the expertise in scalable manufacturing through spray drying, this technology offers a pathway from clinical supplies to commercialization. For the full story, read the complete article by CPHI Content team here.
About Zerion Pharma A/S
ZERION develops its own proprietary drug formulations and offers its Dispersome® technology platform to established pharma companies as a means to solve their challenging drug solubility problems. By applying ZERION’s technology, the solubility of poorly soluble compounds may be greatly enhanced, which improves their oral bioavailability and thereby therapeutic outcomes for the patients.
ZERION was established in 2019 as a spin-out from the University of Copenhagen based on almost a decade of research.
